Gilead downsizes multibillion-dollar deal once at center of CEO's rebuild

Gilead and partner Galapagos no longer will pursue clinical trials in the United States with filgotinib in rheumatoid arthritis and other conditions, but still could pursue the drug as a treatment for inflammatory bowel disease.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.